Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Allergy Therapeutics launches phase I trial of dust mite inoculation

A total of 32 patients will receive Acarovac MPL. The trial is expected to take 12 months from start to finish.
dust mites
Microscopic in size, the problems house dust mites create are significant and include year-round sneezing and asthma.

Allergy Therapeutics plc (LON:AGY) said the phase I clinical study of Acarovac MPL has received official sign-off in Spain.

The trial will assess the safety and how well tolerated the new dust mite treatment is.

A total of 32 patients will receive Acarovac, which will be administered at two different doses. The trial is expected to take 12 months from start to finish.

If the phase I assessment is successful, Allergy Therapeutics will launch the inoculation in Spain on a named-patient basis. This is where doctors can prescribe a drug without it having received regulatory sign-off.

Acarovac MPL is the only house-dust mite immunotherapy in development utilising microcrystalline tyrosine, which is natural and biodegradable.

It also uses monophosphoryl lipid A, or MPL for short, as an adjuvant which enhances the body’s immune response.

Harnessing the two in tandem should improve both safety and efficacy for the thousands suffers, according to Allergy Therapeutics’ boss Manuel Llobet.

The new formulation has the “potential to improve the convenience, adherence and compliance that is essential for a successful treatment, and builds on the acceptance of the existing Acarovac Plus platform”, he added.

Microscopic in size, the problems house dust mites create are significant and include perennial allergic rhinitis (non-seasonal hay fever) and allergic asthma.

The market is worth an estimated US$1.5bn annually.

The shares rose 3% to 25.32p, valuing the business at £150mln. Panmure Gordon in a note on Allergy reckons it is worth a sum-of-the-parts 53p.  Numis thinks the stock is worth 37p.

---Adds share price and broker comment---

Ian_55ae0ddd437b7.jpg
Why Invest In Allergy Therapeutics plc? Read More Here

Register here to be notified of future AGY Company articles
View full AGY profile View Profile

Allergy Therapeutics plc Timeline

Related Articles

Knee surgery
February 02 2017
The treatment involves removing cellular material from animal and human tissue to leave a matrix which gives a framework for population by the patient’s own cells.
GW_Pharma.png
January 11 2017
“[We are] entering a very exciting phase, which should result in the crystallisation of substantial value,” said chief executive, Dr Satu Vainikka.
hepatitisC.jpg
Thu
Regulatory sign-off will fire the starting pistol on the commercial launch in Europe

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use